Dilated Cardiomyopathy Therapeutics Market by Drug class, Treatment Type, Route of Administration, End-User, Distribution Channel

Description

List of Tables

[192 Pages Report] The Dilated Cardiomyopathy Therapeutics Market size was estimated at USD 421.50 million in 2023 and expected to reach USD 456.76 million in 2024, at a CAGR 7.79% to reach USD 712.65 million by 2030.

Global Dilated Cardiomyopathy Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023]	USD 421.50 million
Estimated Year [2024]	USD 456.76 million
Forecast Year [2030]	USD 712.65 million
CAGR (%)	7.79%

Dilated Cardiomyopathy Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Dilated Cardiomyopathy Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Dilated Cardiomyopathy Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Dilated Cardiomyopathy Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amicus Therapeutics, Astellas Pharma Inc, AstraZeneca plc, Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc, C.H. Boehringer Sohn AG & Co. KG, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline (GSK), Johnson & Johnson Services, Inc., Kyowa Kirin Co, Ltd, Merck & Co., Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sarepta Therapeutics, Teva Pharmaceutical Industries Ltd., The Bristol-Myers Squibb Company, The Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Dilated Cardiomyopathy Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug class
- Aldosterone antagonists
- Angiotensin II Receptor Blockers
- Angiotensin-converting enzyme (ACE) Inhibitors
- Beta-blockers
Treatment Type
- Cardioverter-Defibrillators
- Heart Pumps
- Implantable Devices
- Medication
Route of Administration
- Oral
- Parenteral
End-User
- Hospitals
- Research Institutes
- Specialty Clinics
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Dilated Cardiomyopathy Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Dilated Cardiomyopathy Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Dilated Cardiomyopathy Therapeutics Market?

4. What is the market share of the leading vendors in the Dilated Cardiomyopathy Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Dilated Cardiomyopathy Therapeutics Market?

Product Code: MRR-8E22B61932E2

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Dilated Cardiomyopathy Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of cardiovascular diseases and the need for effective treatments
  - 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
  - 5.1.1.3. Government initiatives and programs to raise awareness regarding cardiovascular diseases
- 5.1.2. Restraints
  - 5.1.2.1. High cost of dilated-cardiomyopathy therapeutics
- 5.1.3. Opportunities
  - 5.1.3.1. Applications of precision medicine in the management of dilated cardiomyopathy
  - 5.1.3.2. Ongoing R&D for the development of efficient drugs and therapies for dilated-cardiomyopathy
- 5.1.4. Challenges
  - 5.1.4.1. Side effects associated with the dilated-cardiomyopathy medications
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Dilated Cardiomyopathy Therapeutics Market, by Drug class

6.1. Introduction
6.2. Aldosterone antagonists
6.3. Angiotensin II Receptor Blockers
6.4. Angiotensin-converting enzyme (ACE) Inhibitors
6.5. Beta-blockers

7. Dilated Cardiomyopathy Therapeutics Market, by Treatment Type

7.1. Introduction
7.2. Cardioverter-Defibrillators
7.3. Heart Pumps
7.4. Implantable Devices
7.5. Medication

8. Dilated Cardiomyopathy Therapeutics Market, by Route of Administration

8.1. Introduction
8.2. Oral
8.3. Parenteral

9. Dilated Cardiomyopathy Therapeutics Market, by End-User

9.1. Introduction
9.2. Hospitals
9.3. Research Institutes
9.4. Specialty Clinics

10. Dilated Cardiomyopathy Therapeutics Market, by Distribution Channel

10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy

11. Americas Dilated Cardiomyopathy Therapeutics Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Dilated Cardiomyopathy Therapeutics Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Dilated Cardiomyopathy Therapeutics Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
- 15.1.1. AbbVie Inc.
- 15.1.2. Amgen Inc.
- 15.1.3. Amicus Therapeutics
- 15.1.4. Astellas Pharma Inc
- 15.1.5. AstraZeneca plc
- 15.1.6. Bayer AG
- 15.1.7. Biogen Inc.
- 15.1.8. BioMarin Pharmaceutical Inc
- 15.1.9. C.H. Boehringer Sohn AG & Co. KG
- 15.1.10. Daiichi Sankyo Company, Limited
- 15.1.11. Eli Lilly and Company
- 15.1.12. Gilead Sciences, Inc.
- 15.1.13. GlaxoSmithKline (GSK)
- 15.1.14. Johnson & Johnson Services, Inc.
- 15.1.15. Kyowa Kirin Co, Ltd
- 15.1.16. Merck & Co., Inc.
- 15.1.17. Novartis AG
- 15.1.18. Pfizer Inc.
- 15.1.19. Regeneron Pharmaceuticals, Inc.
- 15.1.20. Roche Holding AG
- 15.1.21. Sanofi S.A.
- 15.1.22. Sarepta Therapeutics
- 15.1.23. Teva Pharmaceutical Industries Ltd.
- 15.1.24. The Bristol-Myers Squibb Company
- 15.1.25. The Takeda Pharmaceutical Company Limited
- 15.1.26. Vertex Pharmaceuticals
- 15.1.27. Viatris Inc.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing